Partnering & Outsourcing Editorial

  1. Clinical News Roundup: New Alzheimer’s Drugs Reach Clinical Trials
    11/3/2017

    Clinical news roundup for the week of October 30, 2017 with information on new Alzheimer’s disease trials, clinical monitoring salaries and turnover, emphasizing patient-centric trials, and GDPR compliance concerns.

  2. Clinical Monitoring Salaries & Turnover Continue To Rise
    10/31/2017

    A 2017 compensation study has found that employee turnover in clinical monitoring jobs outside the U.S. increased significantly in 2016. Turnover in the clinical monitoring job function, which monitors participants’ health during a clinical trial, jumped from 16.4 percent in 2015 to 22.9 percent in 2016, an increase of 40 percent. The increase in turnover was matched, not surprisingly, by increases in salaries for those positions.

  3. Is CRO Consolidation Good For Pharma?
    8/15/2017

    Consolidation continues in the CRO space, with the acquisition of Chiltern by LabCorp being just the latest example of top CROs expanding and increasing their breadth of offerings. As large CROs continue to acquire smaller competitors, can sponsor companies expect to benefit from this development?

  4. 3 Patient-Centric Steps to Increase Retention
    7/26/2016

    Patient centricity is a growing trend in our industry. From the creation of Chief Patient Officer positions to culture-change initiatives, one of the strategies to improve the quality of clinical trials is to treat patients as “consumers” rather than “subjects” in a study.

  5. Clinical News Roundup: GSK Uses Apple ResearchKit For Clinical Research
    7/22/2016

    Clinical news roundup for the week of July 18, 2016 featuring GSK's use of Apple ResearchKit, guidance on first-in-human clinical trials, clinical research transparency in India, nudging patients into clinical trials, and more.

  6. CROs In A Business Exchange With Silicon Valley?
    5/29/2015

    As an applied economic theoretic, by driving out inefficiencies from the current model used by researchers to find and contract with CROs, the Science Exchange should improve the business model for drug discovery. But will all parties — Pharma/Bio, CROs and individual researchers — benefit equally? 

  7. Important Research Growing Complex, Redefining Sponsor/CRO Partnerships
    5/7/2015

    As therapies become more targeted, so does the research to develop those therapies. That means more complex, subject-specific research and more advanced intersections between diagnostics, drugs, and delivery methods to make high-precision medicine possible. This is a future the clinical research community is aware it’s facing. Look no further than the advocacy of patient-centric (and/or patient-centered, contingent on where the interest emanates) research as patients are asked to play a more active role in monitoring their health and, in some cases, administering their medicine, especially as individualized medicines demand varied regimens.

  8. Pharma Outsourcing Trends: Industry Leaders, Equity Financing, And Vendor Consolidation
    2/26/2015

    The outsourcing industry continues to gain a bigger share of the dollars spent on preclinical, clinical, and post approval functions. To accurately quantify the size of various segments of the outsourcing market, this report acknowledges that task is next to impossible. 

  9. ACRES: Ready To Improve The Conduct And Quality Of Clinical Trials
    2/18/2015

    The nonprofit ACRES operates in the public interest, taking a multi-stakeholder approach, forming a true alliance united behind the goal of collaboratively building a system for the clinical research process, based in principles of Accountable Research™.

  10. Improve Clinical Sites By Bringing Together Pharma, Biomedical R&D and CROs
    2/18/2015

    How do you take pharma, and other biomedical R&D, as well as CROS, which for years have operated as separate entities, and get them to come together and create standards and an accreditation process to benefit the entire industry, indeed, the entire enterprise of a complex of multiple stakeholders, including regulators and the public?